![]() Twist has the option to expand the size of the site to accommodate future growth. The new Twist Boston location boasts state-of-the-art antibody discovery workflow tools, including a total of four Berkeley Lights Beacon ® Optofluidic Platforms, for increased screening capacity for discovery projects necessitating ultra-rapid high-content function forward screening. ![]() Antibodies discovered using the DiversimAb platform can be humanized using the Twist antibody optimization (TAO) platform to develop superior biologics for rapid clinical advancement. Twist Boston empowers the development of the next generation of biologics, cell therapies, vaccines, and diagnostics by using its DiversimAb™ family of hyperimmune mouse models to complete discovery and characterization services for global biopharma leaders. Twist Boston, formerly known as Abveris, was acquired by Twist Bioscience in November 2021 to add in vivo antibody discovery expertise to Twist Biopharma’s antibody discovery and optimization capabilities using robust, precisely written synthetic libraries. “Twist is one of the first biotech companies to open a site in Quincy, and we were pleased to find an ideal space that fits our aggressive growth plans to serve our biopharma partners in accelerating antibody discovery for a wide range of therapeutic targets.” Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “This is a year of growth for Twist, as we work to bring the Factory of the Future online in Oregon while expanding our in vivo antibody discovery capacity through our new Twist Boston location,” said Emily M. – J– Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the opening of its new Twist Boston location in Quincy, Massachusetts. We are very pleased to support Syros’s development of new medicines based on the cutting-edge science of gene control.SOUTH SAN FRANCISCO, Calif. By mapping gene control pathways directly in human disease tissue, Syros is pioneering a unique approach to identifying and modulating the gene switches important in diseases and identifying specific patient populations most likely to respond to these gene switches. Syros has built a proprietary platform based on its founders’ seminal discovery of super-enhancers, a new class of gene control elements that provides the company with a unique lens to identify crucial genes that become dysregulated in diseased cells. Syros Pharmaceuticals, based in Cambridge, is focused on discovering and developing novel gene control therapies for cancer and other diseases. We are excited about the potential of Twist Bioscience’s automated platform to significantly lower the cost of DNA synthesis and thereby greatly expand the potential of genetic research. WXHV initially invested in Twist’s Series B financing in May 2014. The Twist platform has the potential to accelerate the application of DNA synthesis in drug development, biofuel and chemical production, agriculture production, biodetection, and data storage. By synthesizing DNA on silicon instead of on traditional 96-well plastic plates, this platform enables cost-effective, rapid, high-quality, and high-throughput synthetic gene production and overcomes the current inefficiencies of synthetic DNA production. We are pleased to share with you that WuXi Healthcare Ventures (WXHV) has joined a $61M Series D financing round of Twist Bioscience and a $40M financing around for Syros Pharmaceuticals.įounded in 2013 in San Francisco, Twist has developed an automated semiconductor-based synthetic gene manufacturing process featuring a 10,000-well silicon platform capable of producing synthetic biology tools, including genes, oligonucleotide pools, and variant libraries.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |